Northland Capital partners view: Dosing of first patients always represents a major milestone in phase 3 trials, as it confirms that preparations have gone to plan and that there are
ImmuPharma PLC (LSE:IMM),, the specialist drug discovery and development company, is pleased to provide a further update on the progress of its Phase III clinical trial of Lupuzor(TM), its lead
ImmuPharma PLC (LSE:IMM) the specialist drug discovery and development company, has told DirectorsTalk about a proposed conditional fund raise of not less than £7.5 million. This includes a proposed conditional non-pre-emptive
ImmuPharma’s Tim McCarthy discusses the progress of Lupuzor, the key milestones for 2016 and a possible re-rating for ImmuPharma shares in this exclusive interview with DirectorsTalk
ImmuPharma PLC (LON:IMM) Chairman Tim McCarthy talks to DirectorsTalk about the recent progress with Lupuzor, opportunities for the company, milestones for 2016 and a re-rating for Immupharma shares? LupuzorTM
Panmure Gordon Analyst – Dr Mike Mitchell “This morning, Immupharma has provided an update on the Lupuzor phase III investigators meeting which was held in Paris on 11th and 12th
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, has given DirectorsTalk a summary of the Investigators Meeting which was held in Paris on 11(th) /12(th) December. The key
ImmuPharma PLC (LSE:IMM) the specialist drug discovery and development company, has given DirectorsTalk a further update on the progress of its Phase III clinical trial of Lupuzor(TM), its lead programme
Panmure Gordon analyst Dr Mike Mitchell spoke about Immupharma PLC this morning “This morning Immupharma has announced a detailed update on the progress of its phase III clinical trial of
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, has provided DirectorsTalk with an update on the progress of its Phase III clinical trial of Lupuzor™, its lead programme
© 2025 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
